B+
Bull case
20%
Probability
Target price
$1.22
Analysis reference price unavailable
Analysis 2025-11-29 · RankAlpha Sentiment AI
TRVI
Trevi TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$0.61
Analysis reference price unavailable
Analysis 2025-11-29 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2025-11-29 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-11-29
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-negative: investors focus on near-term financing and trial readouts while low liquidity amplifies moves. Press and filings emphasize funding needs and program timelines.
RankAlpha Sentiment AI - 2025-11-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31catalystCash runway / financing eventHigh impact
Need for additional financing or successful raise alters dilution expectations and valuation [#10Qp12].
2026-06-30eventAdvancement or readout from CNS pipelineHigh impact
Potential clinical data update or program decision for lead CNS asset could materially move the stock; Trevi focuses on CNS candidates [#10Qp12].
2026-12-31catalystRegulatory setback or negative preclinical signalHigh impact
Adverse safety/efficacy data from trials or regulatory feedback could trigger sharp downside [#PR-2025-09-12].
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-29 • Updated nightlySource: Internal modelMethodology